Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25841| Title: | Impact of inflammatory bowel disease and azathioprine on long-term outcomes after liver transplantation for primary sclerosing cholangitis. | Austin Authors: | Peverelle, Matthew R ;De Cruz, Peter P ;Paleri, Sarang;Gow, Paul J | Affiliation: | Gastroenterology and Hepatology Department of Medicine, University of Melbourne, Parkville, Victoria, Australia Victorian Liver Transplant Unit |
Issue Date: | May-2021 | Date: | 2021-02-11 | Publication information: | Liver Transplantation 2021; 27(5): 770-771 | Abstract: | We read with interest the multicentre retrospective study by Irlès-Depé et al1 reporting the impact of inflammatory bowel disease (IBD) on long-term outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC). In their series PSC-IBD patients were found to have similar rates of death, recurrent PSC (rPSC) and malignancy as patients with isolated PSC. Moreover azathioprine (AZA) exposure was associated with increased mortality, an association which may have been due to an era effect. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/25841 | DOI: | 10.1002/lt.26009 | Journal: | Liver Transplantation | PubMed URL: | 33569894 | Type: | Journal Article | Subjects: | Mortality Recurrent primary sclerosing cholangitis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.